Skip to content
Screener

Exelixis EXEL Net Change in Cash

Net Change in Cash at other companies

Eli Lilly logo
Eli LillyLLY
$3.67B+1,196%
Pfizer logo
PfizerPFE
$563M+50.1%
Kura Oncology logo
Kura OncologyKURA
-$110.02M+36.5%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$45.12M+507%
Immunome logo
ImmunomeIMNM
-$70.79M-162%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$51M-191%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$12.93B+27.4%
Enterprise value$12.82B+26.1%
P/E15×-1.8×
P/S5.3×+0.8×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Exelixis’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:11 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q2 2026
Accession
0000939767-26-000059
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Cash flows from financing activities:
Payments for repurchases of common stock(430,352)(283,934)
Proceeds from issuance of common stock under the equity incentive plan7,47211,627
Taxes paid related to net share settlement of equity awards(34,231)(22,516)
Net cash used in financing activities(457,111)(294,823)
Net decrease in cash and cash equivalents(256,336)(33,622)
Cash and cash equivalents at beginning of period482,488217,374
Cash and cash equivalents at end of period$226,152$183,752

Item 1. Financial Statements.

FAQ

What is Exelixis's net change in cash?
Exelixis (EXEL) reported net change in cash of -$256.34M in Q1 2026.
How has Exelixis's net change in cash changed year-over-year?
Exelixis's net change in cash decreased by 662.4% year-over-year, from -$33.62M to -$256.34M.
What is the long-term trend for Exelixis's net change in cash?
Over 3 years (2021 to 2025), Exelixis's net change in cash has grown at a -8.2% compound annual growth rate (CAGR), from $343.12M to $265.11M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Exelixis's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude